CLINICAL TRIALS PROFILE FOR BRIVARACETAM
✉ Email this page to a colleague
All Clinical Trials for BRIVARACETAM
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00150800 ↗ | This Trial, Evaluating the Long-term Safety and Tolerability of Brivaracetam Will Provide Subjects Suffering From Epilepsy, Who May Have Benefited From Brivaracetam as Adjunctive Treatment, the Opportunity to Receive Open Label Brivaracetam Treatmen | Completed | UCB PHARMA Inc. (US) | Phase 3 | 2006-01-01 | This trial, evaluating the long-term safety and tolerability of brivaracetam will provide subjects suffering from epilepsy, who may have benefited from brivaracetam as adjunctive treatment, the opportunity to receive open label brivaracetam treatment. |
| NCT00160667 ↗ | A Study Assessing Efficacy of Brivaracetam in Subjects With Persistent Pain After Shingles (Post-herpetic Neuralgia) | Completed | UCB Pharma | Phase 2 | 2004-10-11 | Study will assess efficacy, safety and tolerability of brivaracetam in post-herpetic neuralgia (PHN). Duration of 7 weeks divided into 3 periods with no up-titration, nor down-titration. |
| NCT00175825 ↗ | A Dose-ranging Study With Brivaracetam in Patients From 16 to 65 Years With Refractory Partial Onset Seizures. | Completed | UCB Pharma | Phase 2 | 2005-11-07 | This trial will evaluate the efficacy and safety of brivaracetam (at doses of 5, 20 and 50 mg/day in twice a day administration) as add-on therapy in subjects with focal epilepsy. |
| NCT00175916 ↗ | Follow-up Trial to Evaluate Long-term Safety and Efficacy of Brivaracetam in Subjects Suffering From Epilepsy | Completed | UCB Pharma | Phase 3 | 2005-09-01 | This trial, evaluating the long-term safety and tolerability of brivaracetam, will give subjects suffering from epilepsy, who may have benefited from brivaracetam, the opportunity to continue the treatment. The study will also evaluate the maintenance of efficacy over time of brivaracetam for subjects with partial onset seizures (POS)/primary generalized seizures (PGS). |
| NCT00175929 ↗ | A Study of Brivaracetam in Subjects With Partial Onset Seizures | Completed | UCB Pharma | Phase 2 | 2005-05-01 | This trial will evaluate the efficacy and safety of brivaracetam (at doses of 50 and 150 mg/day in twice a day administration) as add on therapy in subjects with focal epilepsy |
| NCT00357669 ↗ | Brivaracetam as add-on Treatment of Unverricht-Lundborg Disease in Adolescents and Adults | Completed | UCB Pharma SA | Phase 3 | 2006-11-01 | The study will compare the efficacy and safety of brivaracetam with placebo in patients with Unverricht-Lundborg disease. |
| NCT00368251 ↗ | Brivaracetam as add-on Treatment of Unverricht-Lundborg Disease (ULD) in Adolescents and Adults | Completed | UCB Pharma | Phase 3 | 2006-11-01 | The study will compare the efficacy and safety of Brivaracetam with placebo in patients with Unverricht- Lundborg Disease (ULD). |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for BRIVARACETAM
Condition Name
Clinical Trial Locations for BRIVARACETAM
Trials by Country
Clinical Trial Progress for BRIVARACETAM
Clinical Trial Phase
Clinical Trial Sponsors for BRIVARACETAM
Sponsor Name
